# Big Data meets Medicines Regulation: Which Data and when?

Luca Pani, MD

EUMTB Chair - CHMP and SAWP Member, EMA — London, UK Dept. of Psychiatry and Behav. Sci., University of Miami — Miami, USA





### Public Declaration of transparency/interests\*

The view and opinions expressed are those of the individual presenter and should not be attributed to AIFA / EMA


| Interests in pharmaceutical industry  | NO | Current | From 0 to 3 previous years | Over 3 previous years |
|---|----|---------|----------------------------|-----------------------|
| DIRECT INTERESTS:   |    |         |                            |                       |
| 1.1 Employment with a company: pharmaceutical company in an executive role              | Х  |         |                            | ☐ mandatory           |
| 1.2 Employment with a company: in a lead role in the development of a medicinal product | Х  |         |                            | ☐ mandatory           |
| 1.3 Employment with a company: other activities   | х  |         |                            | optional              |
| 2. Consultancy for a company  | Х  |         |                            | optional              |
| 3. Strategic advisory role for a company  | Х  |         |                            | optional              |
| 4. Financial interests  | Х  |         |                            | optional              |
| 5. Ownership of a patent  | х  |         |                            | optional              |
| INDIRECT INTERESTS:   |    |         |                            |                       |
| 6. Principal investigator   | Х  |         |                            | optional              |
| 7. Investigator   | Х  |         |                            | optional              |
| 8. Grant or other funding   | х  |         |                            | optional              |
| 9. Family members interests   | х  |         |                            | optional              |




\*Luca Pani, in accordance with the Revised Conflict of Interest Regulations approved by AIFA Board of Directors (25.03.2015) and published on the Official Journal of 15.05.2015 according to EMA policy /626261/2014 on the handling of the conflicts of interest for scientific committee members and experts. NB For this talk I receive NO compensation.

#### Type and Size of Data

#### By 2020 Health Information Will Double Every 73 Days




#### What are we talking here really?



Agenzia Staliana del Farmaco

#### What are we talking here really?



Agenzia Staliana del Farmaco

## 

58%

TRANSITIONING FROM DATA TO KNOWLEDGE IS A MAJOR CHAILFNGF<sup>1</sup>

41%

SYSTEMS CANNOT
PROCESS LARGE
VOLUMES OF DATA FROM
DIFFERENT SOURCES

62%

GROWTH OF UNSTRUCTURED, NON-CONTEXTUALIZED DATA<sup>2</sup>



#### Pillars of Exponential Data Paradigmatic Shock

Unprecedented volumes of public data

ClinicalTrials.gov













Programmatic data transformation:

Deep Learning



Automated categorization

Research

Relative prominence of research activities

Perceived influence on other health care providers

Comparative clinical behavior

Level of engagement with industry






Examples: Monocles; Zephyr Health

#### Innovative data models could be game changer

Traditional, relational model

Entity centric model



#### In summary we are still dealing with...









